PMN

Over the past six months, ProMIS Neurosciences, Inc. experienced several stock-impacting events. In July and August 2026, the company reported positive blinded six-month interim safety and biomarker results from its PRECISE-AD Phase 1b trial of PMN310 for early Alzheimer's disease, showing a favorable safety profile and early biomarker movement, which led to increased analyst price targets. In August 2026, the company announced its second-quarter 2026 financial results and provided a corporate update. A private placement completed in February 2026 generated gross proceeds of $75.5 million, expected to fund operations through 2027. Wall Street sentiment for PMN is uniformly positive, with a "Strong Buy" consensus from analysts. Between September 2025 and September 2026, the share price increased by 26.93%, trading between a 52-week high of $27.40 and a low of $6.27.